The change to Medicare Part B reimbursement of Aduhelm is minor compared to other developments in the saga of the Alzheimer’s drug, sources say, and the temporary financial losses it might cause some doctors would likely be more than offset by the previous overpayments that Medicare was making for the drug. CMS plans to change the doctor-payment formula for Aduhelm because the average sales price it normally uses was double the “widely available market price,” or WAMP, after Biogen halved...